Almirall Expands Dermatology Portfolio with New Clinical Data at AAD 2026
Event summary
- Almirall presented over 15 scientific posters at the 2026 AAD Annual Meeting, covering atopic dermatitis, psoriasis, actinic keratosis, and acne.
- The company highlighted 9 lebrikizumab presentations in atopic dermatitis, including long-term safety and real-world effectiveness data.
- New analyses on tirbanibulin for actinic keratosis and tildrakizumab for psoriasis were also featured.
- Sarecycline for acne was supported by pooled Phase 3 evaluations.
The big picture
Almirall's robust data presentation at AAD 2026 underscores its commitment to advancing medical dermatology. The company's focus on real-world evidence and long-term safety data aligns with broader industry trends toward patient-centric outcomes and evidence-based treatments. With a portfolio spanning inflammatory and proliferative skin conditions, Almirall is positioning itself as a key player in the dermatology space, leveraging strong partnerships and continuous R&D investment.
What we're watching
- Clinical Validation
- How the new real-world evidence for lebrikizumab will impact its adoption in atopic dermatitis.
- Market Differentiation
- Whether Almirall can sustain its competitive edge with tirbanibulin in actinic keratosis.
- Regulatory Dynamics
- The pace at which Almirall can expand the indications for tildrakizumab in psoriasis.
Related topics